Clinical Trials Browser

Phase 1/2 × Brain Neoplasms × Bevacizumab × Clear all

NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04121455 2025-06-25

GLORIA

Phase 1/2 Active not recruiting

Brain Neoplasms, Glioblastoma

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02052648 2024-03-27

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Phase 1/2 Completed

160 enrolled 21 charts

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT01811498 2024-01-30

Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM

Phase 1/2 Completed

31 enrolled 7 charts

Brain Neoplasms, Glioblastoma

NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Phase 1/2 Completed

121 enrolled 27 charts

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT00924820 2020-12-31

A Pilot Study of Bevacizumab for Neoplastic Meningitis

Phase 1/2 Completed

20 enrolled 7 charts

Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Meningeal Carcinomatosis

NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Phase 1/2 Terminated

12 enrolled 7 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 1/2 Completed

116 enrolled 17 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT01290263 2017-07-02

Amgen 386 for Recurrent Glioblastoma

Phase 1/2 Completed

48 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Glioma

NCT02065466 2016-04-21

Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases

Phase 1/2 Withdrawn

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01189240 2015-12-14

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

Phase 1/2 Terminated

13 enrolled 13 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT00939991 2013-06-24

Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Phase 1/2 Completed

48 enrolled 12 charts

Brain Neoplasms, Glioblastoma